Aminoglycoside nephrotoxicity

Seminars in Nephrology

Volumn 17, Issue 1, 1997, Pages 27-33

  Swan, Suzanne K ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; POLYAMINE; POLYANION; POLYASPARTIC ACID; POTASSIUM CHLORIDE;

BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INDUCED DISEASE; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY FAILURE; NEPHROTOXICITY; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AMINOGLYCOSIDES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE;

EID: 0031013486     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Waksman SA, Bugie E, Schatz A: Isolation of antibiotic substances from soil microorganisms with special reference to streptothricin and streptomycin. Proc Staff .Meet Mayo Clin 19:537-548, 1944
2. Brushwood DB: Government liable for failure to monitor a patient's serum gentamicin concentration in an Army hospital. Am J Hosp Pharm 49:1748-1750, 1992
3. Gyselynck AM, Forrey A, Cutler R: Pharmacokinetics of gentamicin: Distribution and plasma and renal clearance. J Infect Dis 124:70-76, 1971 (suppl 124)
4. Pastoriza-Munoz E, Bowman RL, Kaloyanides GJ: Renal tubular transport of gentamicin in the rat. Kidney Int 16:440-450, 1979
5. Senekjian HO, Knight TF, Weinman EJ: Micropuncture study of the handling of gentamicin by the rat kidney. Kidney Int 19:416-423, 1981
6. Sastrasinh M, Knauss TC, Weinberg JM, et al: Identifi-cation of the aminoglycoside binding site in rat renal brush border membranes. J Pharmacol Exp Ther 222:350-358, 1982
7. 1 kidney epithelial cell line. J Pharmacol Exp Ther 268:669-674, 1994
8. 1). J Pharmacol Exp Ther 261:1200-1205, 1992
9. Silverblatt FJ, Kuehn C: Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 15:335-345, 1979
10. Dominguez JH, Hale CC, Qulali M: Studies of renal injury. I. Gentamicin toxicity and expression of basolateral transporters. Am J Physiol 270:F245-F253, 1996
11. Kosek JC, Mazze RI, Cousins MJ: Nephrotoxicity of gentamicin. Lab Invest 30:48-57, 1974
12. Houghton DC, Hartnett M, Campbell-Boswell M, et al: A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Am J Pathol 82:589-612, 1976
13. Todd JH, Hottendorf GH: Renal brush border membrane vesicle aminoglycoside binding and nephrotoxicity. J Pharmacol Exp Ther 274:258-263, 1995
14. 1 by aminoglycosides is a novel variant of substrate depletion inhibition. J Pharmacol Exp Ther 254:188-191, 1990
15. Kaloyanides GJ: Aminoglycoside-induced functional and biochemical defects in the renal cortex. Fundam Appl Toxicol 4:930-943, 1984
16. Josepovitz C, Farruggella T, Levine R, et al: Effect of netilmicin on the phospholipid composition of subcellular fractions of rat renal cortex. J Pharmacol Exp Ther 235:810-819, 1985
17. Laurent G, Carlier MB, Rollman B, et al: Mechanism of aminoglycoside-induced lysosomal phospholipidosis: In vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol 31:3861-3870, 1982
18. Josepovitz C, Levine R, Lane B, et al: Contrasting effects of gentamicin and mercuric chloride on urinary excretion of enzymes and phospholipids in the rat. Lab Invest 52:375-386, 1985
19. Ibrahim S, Van der Auwera P, Meunier F, et al: Effect of netilmicin and amikacin on urinary phospholipids excre tion in humans. Arch Toxicol Suppl 13:413-416, 1989
20. Josepovitz C, Levine R, Farruggella T, et al: Comparative effects of aminoglycosides on renal cortical and urinary phospholipids in the rat. Proc Soc Exp Biol Med 182:1-5, 1986
21. Luft FC, Bloch R, Sloan RS, et al: Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis 138:541-545, 1978
22. Williams PD, Bennett DB, Gleason CR, et al: Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 31:570-574, 1987
23. Lullmann H, Lullmann-Rauch R, Wassermann O: Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 4:185-218, 1975
24. Kaloyanides GJ: Drug-phospholipid interactions: Role in aminoglycoside nephrotoxicity. Ren Fail 14:351-357, 1992
25. 1. J Pharmacol Exp Ther 231:48-55, 1984
26. Ramsammy LS, Josepovitz C, Kaloyanides GJ: Gentamicin inhibits agonist stimulation of the phosphatidylinositol cascade in primary cultures of rabbit proximal tubular cells and in rat renal cortex. J Pharmacol Exp Ther 247:989-996, 1988
27. Ramsammy L, Josepovitz C, Lane B, et al: Polyaspartic acid inhibits gentamicin-induced pertubations of phospholipid metabolism. Am J Physiol 258:C1141-C1149, 1990
28. Walker PD, Shah SV: Gentamicin enhanced production of hydrogen peroxide by renal cortical mitochondria. Am J Physiol 253:C495-9, 1987
29. Ramsammy LS, Josepovitz C, Ling KY, et al: Failure of inhibition of lipid peroxidation by vitamin E to protect against gentamicin nephrotoxicity in the rat. Biochem Pharmacol 36:2125-2132, 1987
30. Weisblum B, Davies J: Antibiotic inhibitors of the bacterial ribosome. Bacteriol Rev 32:493-528, 1968 (suppl)
31. Buss WC, Piatt MK: Gentamicin administered in vivo reduces protein synthesis in microsomes subsequently isolated from rat kidneys but not from rat brains. J Antimicrob Chemother 15:715-721, 1985
32. Bennett WM, Mela-Riker LM, Houghton DC, et al: Microsomal protein synthesis inhibition: An early manifestation of gentamicin nephrotoxicity. Am J Physiol 255:F265-269, 1988
33. 1 Chem Pharm Bull 40:3307-3310, 1992
34. Nonclercq D, Toubeau G, Lambricht P, et al: Redistribution of epidermal growth factor immunoreactivity in renal tissue after nephrotoxin-induced tubular injury. Nephron 57:210-215, 1991
35. Toubeau G, Nonclercq D, Zanen J, et al: Distribution of epidermal growth factor in the kidneys of rats exposed to amikacin. Kidney Int 40:691-699, 1991
36. Cronin RE, Nix KL, Ferguson ER, et al: Renal cortex ion composition and Na-K-ATPase activity in gentamicin nephrotoxicity. Am J Physiol 242:F477-483, 1982
37. Fish EM, Moutons BA: Alterations in epithelial polarity and the pathogenesis of disease states. N Engl J Med 330:1580-1588, 1994
38. Cojocel C, Dociu N, Maita K, et al: Effects of aminoglycosides on glomerular permeability, tubular reabsorption, and intracellular catabolism of the cationic low-molecularweight protein lysozyme. Toxicol Appl Pharmacol 68:96109, 1983
39. Schwartz JH, Schein P: Fanconi syndrome associated with cephalothin and gentamicin therapy. Cancer 41:769-772, 1978
40. Elliott WC, Patchin DS: Aminoglycoside-mediated calciuresis. J Pharmacol Exp Ther 262:151-156, 1992
41. Garland HO, Birdsey TJ, Davidge CG, et al: Effects of gentamicin, neomycin and tobramycin on renal calcium and magnesium handling in two rat strains. Clin Exp Pharmacol Physiol 21:109-115, 1994
42. Foster JE, Harpur ES, Garland HO: An investigation of the acute effect of gentamicin on the renal handling of electrolytes in the rat. J Pharmacol Exp Ther 261:38-43, 1992
43. Costa Suva VL, Zaladek G, Nascimento G, et al: Effect of gentamicin on urinary acidification in the rat. Renal Physiol 9:204-212, 1986
44. Gordon JA, Dillingham MA, Guggenheim SJ, et al: The renal concentrating defect after gentamicin administration in the rat. J Lab Clin Med 101:903-910, 1983
45. Zager RA: Sepsis-associated acute renal failure: Some potential pathogenetic and therapeutic insights. Nephrol Dial Transplant 9:164-167, 1994 (Suppl 4)
46. Zager RA: Endotoxemia, renal hypoperfusion, and fever: Interactive risk factors for aminoglycoside and sepsisassociated acute renal failure. Am J Kidney Dis 20:223-230, 1992
47. Zager RA: Gentamicin nephrotoxicity in the setting of acute renal hypoperfusion. Am J Physiol 254:F574-F581, 1988
48. Thompson JR, Simonsen R, Spindler MA, et al: Protective effect of KC1 loading in gentamicin nephrotoxicity. Am J Kidney Dis 15:583-591, 1990
49. Quarum ML, Houghton DC, Gilbert DN, et al: Increasing dietary calcium moderates experimental gentamicin nephrotoxicity. J Lab Clin Med 103:104-114, 1984
50. Humes HD, Sastrasinh M, Weinberg JM: Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity. J Clin Invest 73:134-147, 1984
51. Kacew S: Inhibition of gentamicin-induced nephrotoxicity by pyridoxal-5′-phosphate in the rat. J Pharmacol Exp Ther 248:360-366, 1989
52. Mohandass S, Sandhya P, Varalakshmi P: Prevention of urinary biomolecular losses by DL α-lipoic acid in gentamicin-treated rats. Med Sei Res 23:41-43, 1995
53. Kojima R, Ito M, Suzuki Y: Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (7): Effect of latamoxef on binding of tobramycin to brush border membranes isolated from rat kidney cortex. Jpn J Pharmacol 51:465-473, 1989
54. Couture M, Simard M, Gourde P, et al: Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin. Antimicrob Agents Chemother 38:742-749, 1994
55. Kojima R, Ito M, Suzuki Y: Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (9): Protective effect of inositol hexasulfate against tobramycin-induced nephrotoxicity. Jpn J Pharmacol 53:347-358, 1990
56. Beauchamp D, Laurent G, Maldague P, et al: Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-L-aspartic acid and poly-L-asparagine in rats. Arch Toxicol Suppl 9:306-309, 1986
57. Kishore BK, Lambricht P, Laurent G, et al: Mechanism of protection afforded by polyaspartic acid against gen-tamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids. J Pharmacol Exp Ther 255:875-885, 1990
58. Kishore BK, Kdllay Z, Lambricht P, et al: Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phopholipid layers in vitro. J Pharmacol Exp Ther 255:867-874, 1990
59. Gilbert DN, Wood ÇA, Kohlhepp SJ, et al: Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis 159:945-953, 1989
60. Swan SK, Kohlhepp SJ, Kohnen PW, et al: Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity. Antimicrob Agents Chemother 35:25912595, 1991
61. Swan SK, Gilbert DN, Kohlhepp SJ, et al: Duration of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity. Antimicrob Agents Chemother 36:2556-2558, 1992
62. Swan SK, Gilbert DN, Kohlhepp SJ, et al: Pharmacologie limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity. Antimicrob Agents Chemother 37:347-348, 1993
63. Reinhard MK, Bekersky I, Sanders TW, Jr., et al: Effects of polyaspartic acid on pharmacokinetics of tobramycin in two strains of rat. Antimicrob Agents Chemother 38:79-82, 1994
64. English J, Gilbert DN, Kohlhepp S, et al: Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother 27:897-902, 1985
65. Davis BD: Mechanism of bactericidal action of aminoglycosides [published erratum appears in Microbiol Rev 1988 Mar;52(l):153]. Microbiol Rev 51:341-350, 1987
66. Craig WA, Vogelman B: The postantibiotic effect. Ann Intern Med 106:900-902, 1987
67. Morin JP, Viotte G, Vandewalle A, et al: Gentamicininduced nephrotoxicity: A cell biology approach. Kidney Int 18:583-590, 1980
68. Matzke GR, Lucarotti RL, Shapiro HS: Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol 3:11-17, 1983
69. Li SC, loannides-Demos LL, Spicer WJ, et al: Prospective audit of an aminoglycoside consultative service in a general hospital. Med J Aust 157:308-311, 1992
70. Bertino JS, Jr., Booker LA, Franck PA, et al: Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167:173-179, 1993
71. MacGowan A, Reeves D: Serum aminoglycoside concentrutions: The case for routine monitoring. J Antimicrob Chemother 34:829-837, 1994
72. Leehey DJ, Braun BI, Tholl DA, et al: Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 4:81-90, 1993
73. Hickling KG, Begg EJ, Perry RE, et al: Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med 19:1041-1047, 1991
74. Bennett WM, Plamp CE, Gilbert DN, et al: The influ-ence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure. J Infect Dis 140:576-580, 1979
75. Barclay ML, Begg EJ, Hickling KG: What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 27:32-48, 1994
76. Prins JM, Biiller HR, Kuijper EJ, et al: Once versus thrice daily gentamicin in patients with serious infections. Lancet 341:335-339, 1993
77. Van der Auwera P, Meunier F, Ibrahim S, et al: Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 35:640-647, 1991
78. Ibrahim S, Derde MP, Kaufman L, et al: Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease. Ren Fail 12:199-203, 1990
79. ter Braak EW, de Vries PJ, Bouter KP, et al: Oncedaily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus ceftriaxone. Am J Med.89:58-66, 1990
80. EORTC International Antimicrobial Therapy Cooperative Group: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119:584-593, 1993
81. Tulkens PM, Clerckx-Braun F, Donnez J, et al: Safety and efficacy of aminoglycosides once-a-day: Experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev 1:71-82, 1988
82. Nicolau DP, Freeman CD, Belliveau PP, et al: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39:650-655, 1995
83. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults. A meta-analysis. Ann Intern Med 124:717-725, 1996